AAX Biotech’s Seqitope™ Technology Set to Revolutionize Antibody-Based Treatments for Neurodegenerative Diseases
Biopharma company BioArctic AB has announced that it will use AAX Biotech’s proprietary epitope mapping technology, Seqitope™, to develop antibody-based treatments for neurodegenerative diseases. This marks a significant milestone for AAX Biotech, highlighting its role in advancing research and innovation in the rapidly growing market for next-generation antibody therapeutics.
AAX Biotech is dedicated to addressing unmet needs in the field of antibody-based medicines. Its two pioneering technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of these treatments and provide a unique solution in this rapidly growing market. With this partnership with BioArctic, AAX Biotech is taking a major step towards advancing research and contributing to the fight against debilitating diseases that affect millions of people worldwide.
“We are thrilled to have BioArctic use our technology,” says Maria L. Knudsen, CEO of AAX Biotech. “This project represents a unique opportunity for us to contribute to the development of effective treatments for neurodegenerative diseases, which have a huge impact on the lives of so many people.”
For more information about AAX Biotech and its technologies, please visit [website link]. To learn more about BioArctic’s work on neurodegenerative disease treatments, please visit [website link].
